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Background. Idiopathic pulmonary ﬁbrosis (IPF) is a progressive ﬁbrotic interstitial lung disease with ineﬀective treatment. My-
cophenolate mofetil (MMF) is an immunomodulatory agent which inhibits lymphocyte proliferation. Objective.W es o u g h tt o
determine the safety and eﬃcacy proﬁle of MMF in IPF patients. Methods. We retrospectively identiﬁed ten patients, who met
the ATS/ERS 2000 criteria for IPF and received MMF 2gr/day for 12 months. All of them had routine laboratory, pulmonary
function and radiological (high resolution computed tomography-HRCT) data available and were enrolled in the study. Forced
vital capacity (FVC), total lung capacity (TLC), diﬀusion capacity of the lung for carbon monoxide (DLCO), 6-minute walking
distance (6MWD), HRCT scans and routine laboratory data at treatment onset were compared with respective values 12 months
aftertreatment onset.Results. Therewere nosigniﬁcantalterationsinFVC, TLC,DLCO and6MWDpre- and6and12monthspost-
treatment. HRCT evaluation showed deterioration of the total extent of disease (P = 0.002) and extent of ground-glass opacity
(P = 0.02). No cases of clinically signiﬁcant infection, leucopenia, or elevated liver enzymes were recorded. Conclusions. MMF is a
safe therapeutic modality which failed to show a beneﬁcial eﬀect both in functional and radiological parameters in a small cohort
of IPF patients.
1.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is an irreversible, dev-
astating, progressive type of lung ﬁbrosis that culminates in
a fatal outcome irrespective of treatment [1]. Despite innu-
merable research studies and rapid expansion of scientiﬁc
knowledge, IPF pathogenesis still remains elusive and con-
troversial [2–5].Recentdata strongly suggest that themecha-
nisms driving IPF reﬂect abnormal deregulated wound heal-
inginresponse tomultiplesitesofongoingalveolarepithelial
injury ofunknown originleading toﬁbroblastactivationand
exaggerated accumulation of extracellular matrix into the
lung parenchyma [2–6]. Therefore, our present understand-
ing of the molecular and cellular pathways has resulted in
the testing of therapeutic approaches that modulate speciﬁc
inﬂammatory and ﬁbrotic mediators. With a gradually in-
creasing worldwide incidence and no proven therapies other
than lung transplantations, IPF treatment is a major chal-
lenge for chest physicians [7–9].
Mycophenolate mofetil (MMF), an inhibitor of lympho-
cytes proliferation through blockade of inosine monophos-
phate dehydrogenase and interference with purine biosyn-
thesis,iscommonlyusedtopreventrejectionfollowingsolid-
organ transplantation [10–14]. Its clinical utility has been
expanded for the treatment of severalautoimmune and renal
disorders [15]. MMF languished in relative obscurity until
the past 5 years when it emerged to function not only as
an anti-inﬂammatory but also as an antiproliferative agent
by downregulating the expression of several critical growth
factorsincludingtransforming growthfactor- (TGF-)β.T h i s2 Pulmonary Medicine
property makes it an attractive candidate drug for the treat-
ment of ﬁbrotic lung disease [16].
H o w ev e r ,t h e r ei sas e r i o u sl a c ko fk n o w l e d g ea n dc l i n i c a l
experience regarding its safety, tolerability, and eﬃcacy in
patients with IPF, a disease with ineﬀective treatment and a
dismalprognosis.This retrospective studyseekstodetermine
the safety proﬁle and demonstrate the eﬀectiveness of MMF
treatment during the disease course in a small cohort of IPF
patients.
2.PatientsandMethods
2.1. Patients. This is a retrospective, single-center trial esti-
mating the safety and eﬃcacy of MMF for IPF treatment.
After approval by the Local Ethics Committee and the
Institutional ScientiﬁcReviewBoard (referencenumber 45/4
Scientiﬁc Committee-16/11/2009) patients (n = 10) were
retrospectively identiﬁed who met the ATS/ERS 2000 criteria
for IPF [1]a n dr e c e i v e d ,o na no ﬀ-label basis, MMF 2gr/day
for >6 months, between September 2006 and October 2008.
Mean time from diagnosis drug initiation was 9 ± 2m o n t h s .
Patients who had no serial routine laboratory, functional,
and radiological data available were excluded from the anal-
ysis (n = 0). Patients were evaluated on an outpatient basis
at the Department of Pneumonology, University Hospital of
Alexandroupolis, Democritus University of Thrace, Greece.
All patients gave informed consent.
2.2. Assessment of High-Resolution Computer Tomography
(HRCT) Data. High-resolution CT sections (1mm) were
acquiredsupine,atfullinspiration,at10mmintervalsrecon-
structed with bone algorithm using a spiral CT scanner (GE
Prospeed Series). The scans were scored by a thoracic radiol-
ogist with 9 years of experience (A. Oikonomou), blinded to
clinical and lung function information [17]. HRCT images
were scored at ﬁve predetermined levels: (1) origin of great
vessels, (2) main carina, (3) pulmonary venous conﬂuence,
(4) halfway between the third and ﬁfth section, and (5)
immediately above the right hemidiaphragm. HRCT vari-
ables evaluated were total disease extent, the extent of retic-
ular pattern, the extent of ground-glass, the proportion of
ground-glass opacity, and the coarseness of reticular disease.
2.2.1. Extent of Disease. The total extent of interstitial lung
disease was estimated to the nearest ﬁve percent in each of
theﬁvesections, withglobalextentofdisease onHRCTcom-
puted as the mean of the scores.
2.2.2. Extents of Individual Patterns. HRCT patterns were
subdivided into reticular disease (innumerable interlacing
line shadows that were ﬁne, intermediate, or coarse, with
variable associated distortion of the lung architecture) and
ground-glass attenuation (a hazy increase in lung parenchy-
mal attenuation, with preservation of bronchial and vascular
markings) [18] .T h er e l a t i v ep r o p o r t i o n so ft h et w op a t t e r n s ,
estimated in each section, were multiplied by the total extent
of disease to provide separate extent scores for each pattern,
withtheglobalscorescomputedasmeanvalues,asforoverall
Table 1: Baseline characteristics of the study population.
Characteristics Baseline data
Subjects 10
Male 10
Female 0
Age (years) 63 (44–73)
Smokers 0
Ex-smokers 10
Nonsmokers 0
Prior treatment (steroids) received 3
Other treatment received 3
VATS 6
FVC %pred 59.2 ± 17.1
TLC %pred 53.9 ±10.2
DLCO %pred 39.4 ± 9.3
6MWD (meters) 441 ±124.5
PA-aO2 (mmHg) 27.4 ±11.5
sPAP (by echocardiography) mmHg 37.2 ± 19.6
Dataarepresentedasmedian(range),no(total)ormean ±SD,unlessstated
otherwise.
6MWD: 6-minute walking distance, FVC: forced vital capacity, NA: nonap-
plicable, PA-aO2: alveolar-arterial gradient of oxygen tension, sPAP: systolic
p u l m o n a r ya r t e r yp r e s s u r e ,T L C :t o t a ll u n gc a p a c i t y .
disease extent. From these scores, the contribution made by
ground glass to overall disease extent was calculated (pro-
portion of ground glass).
2.2.3. Coarseness of Reticulation. The most severe disease in
each section was quantiﬁed as grade 0 = ground glass atten-
uation alone, grade 1 = ﬁne intralobular ﬁbrosis, grade 2 =
microcystic honeycombing (air spaces less than or equal to
4mmindiameter),andgrade3= macrocystic honeycomb-
ing (air spaces greater than 4mm in diameter). The total
coarseness score was the summed score for all ﬁve levels
(range 0 to 15).
2.3. Statistical Analysis. Continuous data are presented as
medians with ranges or mean + SD. The paired two-tailed
Student’s t-test was used to assess statistically signiﬁcant dif-
ferences in functional parameters at baseline and 12 months
after treatment. Linear regression analysis was used to deter-
mine whether there was any improvement in FVC, TLC, and
DLCO 6 and 12 months after MMF treatment initiation. The
paired Wilcoxon signed ranks test, nonparametric tests were
employed to analyse radiological ﬁndings. Statistical analysis
was performed with SPSS software, version 17.0.
3.Results
3.1. Baseline Characteristics. Baseline characteristics of pa-
tients enrolled in the study are shown in Table 1.A sd e m o n -
strated, all patients were male, 9 out of 10 (90%) were ex-
smokers, at the time of treatment initiation. Six out of
10 patients (60%) had histopathological biopsy provenPulmonary Medicine 3
Table 2: FVC, TLC, DLCO,6 M W D ,a n dP A-aO2 at baseline and 6 and 12 month after MMF treatment.
B a s e l i n e 6m o n t h s 1 2m o n t h s P-value1 P-value2
FVC (%) pred 59.2 ± 17.1 58.2 ± 17.2 55 ± 14.9 0.228 0.081
TLC (%) 53.9 +10.2 53.6 +12.3 52 ±12.8 0.702 0.081
DLCO (%) 39.4 + 9.3 38.5 + 9 35.2 + 8.8 0.47 0.053
6MWD 441 +124 NA 421 + 123 NA 0.09
PA-aO2 27.4 +11.5 NA 27.7+11.2 NA 0.67
Data are presented as mean ± SD unless stated otherwise, P-value1: between baseline and 6 months, P-value2: between baseline and 12 months;
6MWD: 6-minute walking distance, FVC: forced vital capacity, NA: nonapplicable, PA-aO2: alveolar-arterial gradient of oxygen tension, TLC: total lung
capacity.
IPF/usual interstitial pneumonia (UIP) whereas in the re-
maining four diagnosis was based on the radiological UIP
pattern. Seven out of 10 patients (70%) were previously un-
treated whereas the remaining three patients had used
low doses of corticosteroids (two under 20mgrs and one
under 10mgrs of methylprednisdone daily), at the time
of treatment initiation. In addition, three patients (30%)
had pulmonary hypertension at the time of MMF initiation
(sPAP greater than 60mmHg, with an overall mean sPAP =
37.2 + 19.6mmHg) estimated by echocardiography and
were started with endothelin-receptor antagonists (one with
250mgrs of bosentan and the remaining two with 10mgrs
of ambrisentan). Underlying autoimmunity was excluded
by the absence of signs of arthritis, morning stiﬀness,
sclerodactyly, photosensitivity, and Raynaud’s phenomenon
coupled with negative immunologic proﬁle (antinuclear
antibodies-ANA, anti-ds DNA antibodies, and rheumatoid
factor) in eight out of ten patients. Two patients had positive
ANA antibodies, with a negative remaining immunologic
proﬁle and physical examination, in the remaining two pa-
tients,whichcouldnotverifythepresenceofanautoimmune
disorder.
3.2. MMF Treatment Failed to Show Disease Improvement
Based on Pulmonary Function Parameters . As demonstrated
in Table 2 and Figures 1 and 2, MMF treatment failed to
show a beneﬁcial eﬀect as assessed by pulmonary function
parameters. Linear regression analysis showed that FVC(P =
0.228, P = 0.081), TLC (P = 0.70, P = 0.081), and DLCO
(P = 0.47, P = 0.053) did not change signiﬁcantly both 6
and 12 months after MMF treatment initiation, respectively.
Inaddition,MMFadministration wasassociatedin6-minute
walking distance (6MWD) at baseline and 12 month after
treatment (P = 0.09). Finally, no alterations in alveolar-
arterial gradient of oxygen tension (PA-aO2) between pre-
and 12 posttreatment levels (P = 0.67) were noted.
3.3. MMF Treatment Was Associated with Disease Progression
Based on High-Resolution Computed Tomography (HRCT)
Data. Eight out of 10 IPF patients treated with MMF had
HRCT evaluation before and after treatment with mean
time interval between the two HRCT scans of 12 months.
The remaining 2 patients had HRCT evaluation only before
initiation of MMF treatment because they died due to acute
exacerbation and therefore there was no data available.
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Figure 1: Forced vital capacity (FVC) ﬂuctuations over time for
each subject. Each line represents measurements made in a single
subject. A time point 0 month indicates when MMF treatment was
commenced.
Among the eight patients who had HRCT evaluation
both before and after initiation of MMF treatment the mean
HRCT scores for the HRCT variables are shown in Table 3.
Statistical analysis showed that there was disease progression
based on the total extent of disease (P = 0.002) and extent
of ground-glass opacity (P = 0.02) while there was no
signiﬁcant change concerning the extent of reticular pattern,
theproportionofground-glassopacity,andthecoarseness of
reticular disease (P>0.05).
3.4.Clinical andLaboratoryAcceptableSafetyProﬁle. Patients
were followed for 12 months with routine laboratory tests,
includingliverenzymesandwhitebloodcellscount.Nocases
of liver toxicity, clinically signiﬁcant infection, and leucope-
niawererecordedduringMMFtreatment.Inaddition,MMF
was well tolerated by all patients with no development of
abdominalpain,nausea,orvomitingepisodesthatcouldlead
to treatment discontinuationordosagereduction. The above4 Pulmonary Medicine
Table 3: HRCT scores before and after MMF treatment.
Disease
extent
0m o n t h
Reticular
extent
0m o n t h
GGO
extent
0m o n t h
Coarseness
reticulation
0m o n t h
Proportion
GGO
0m o n t h
Disease
extent
12 months
Reticular
extent
12 months
GGO
extent
12 months
Coarseness
reticulation
12 months
Proportion
GGO
12 months
1 23 23 5,2 9 22,6 28 18,7 9,3 9 33,21
2 23 10,5 12,5 8 54 52 34,8 17,2 10 32
3 25 22,5 2,5 11 10 28 17,2 10,8 11 38,57
4 59 31,3 27,7 12 47 67 35,1 31,9 12 47,6
5 38 18,2 19,8 10 52,1 64 40,4 23,6 13 36,8
6 32 19,3 15,3 9 36,9 33 29,9 19,2 11 36,9
7 33 20,1 14,9 11 37,8 35 31,2 25,2 13 35,8
8 31 22,1 11,2 10 36,9 46 30,9 26,2 10 39,2
Mean 33 20,7 13,6 10 37,02 44 29,7 20,42 11 37,5
P-value 0.002∗ >0.05 0.02∗ >0.05 >0.05
HRCT: high-resolution computed tomography, MMF: mycophenolate mofetil, GGO: ground-glass opacity.
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Figure 2: Diﬀusion capacity of the lung for carbon monoxide
(DLCO) ﬂuctuations over time for each subject. Each line represents
measurements made ina single subject. A time point0 monthindi-
cates when MMF treatment was commenced.
datasuggestthatMMFhasan acceptablesafety andtolerabil-
ity proﬁle.
4.Discussion
This is the ﬁrst report in theliterature investigating the safety
and eﬃcacy proﬁle of a novel immunomodulatory agent,
MMF, given to a small cohort of IPF patients. We retrospec-
tively collected laboratory, functional, and radiological data
and demonstrated a readily acceptable safety proﬁle with no
important adverse events justifying drug discontinuation or
dosage reduction. Regarding drug eﬀectiveness, MMF treat-
ment failed to show a beneﬁcial eﬀect as assessed by func-
tional parameters (FVC, TLC, DLCO,6 M W D ,a n dP A-aO2)
while disease progression based on HRCT data, as assessed
by using a highly standardized scoring system, was seen.
Thepharmacologicaltreatmentthatiscurrentlyavailable
for IPF is clearly inadequate [8, 19–25]. The emergence of
novel and powerful tools have provided scientists and physi-
cians with numerous avenues of investigation with clinical
applications to greatly improve our understanding of IPF
pathogenesis. However, this fatal disease still remains with-
out proven therapies other than lung transplantations given
to a small minority of individuals [7, 9]. In view of the cur-
rent disappointing survival data arising from large prospec-
tive placebo-controlled clinical trials, many chest physicians
worldwide apply other therapeutic regimens to attempt IPF
treatment.
MMF has been extensively used to downregulate host-
immune response following solid-organ transplantation and
therefore to preventrejection [10–14, 26]. In addition, MMF
has been also proven eﬀective in the treatment of several
autoimmune and renal disorders, including systemic lupus
erythematosus [15]. Based on the versatile anti-inﬂammato-
ry and immunomodulatory properties of its active metabo-
lite, mycophenolic acid, MMF treatment has been recently
applied with promising results in patients with systemic scle-
rosis (SSc) with interstitial lung involvement.
In particular, Liossis et al. demonstrated a beneﬁcial ef-
fect of MMF both in functional and radiological parameters
in ﬁve patients with SSc-associated alveolitis [27]. Moreover,
MMF administration was well tolerated and safe showing
no serious adverse events. Further extending their results,
Gerbino etal., retrospectively identiﬁed13patientswithSSc-
interstitial lungdisease who were treatedwithMMFand sug-
gested that MMF improves vital capacity 12 months afterPulmonary Medicine 5
treatment [28]. Findings were also replicated by another
group of investigators in a small cohort of SSc patients with
interstitial lung disease, where authors reported a beneﬁcial
eﬀectof MMF on the functional status of these patients [29].
Since T cells seem to play a vital role in the pathogenesis of
scleroderma and mycophenolic acid inhibits, via blockage of
inosine monophosphate, T-cell proliferation and downreg-
ulates their intracellular adhesion to endothelial cells, it is
highly possible that a beneﬁcial eﬀect of this drug might be
anticipated.
Fueledby thisprospect and based onthe aforementioned
promising results, US investigators have recently launched a
large multicentre randomized clinical trial to compare the
beneﬁcial eﬀect in lung function parameters of a 2-year
course of MMF with those of a 1-year course of oral cy-
clophosphamide,inpatientswith symptomatic scleroderma-
related interstitial lung disease. This trial is still ongoing and
its results are greatly anticipated (for more information go to
http://clinicaltrials.gov/).
In past years, the role of T cells in the pathogenesis of IPF
was relatively overlooked mainly due to the disappointing
results of corticosteroid treatment. However, interest in the
role of autoimmunity in IPF pathophysiology was revived
by a study showing that CD4+ cells in IPF patients are in
a highly activated status and proliferate rigorously when
stimulated with IPF lung extracts, suggesting the presence of
an autoimmune process through recognition of self-antigens
[30].Inlinewiththispremise,ourstudygroupdemonstrated
a numerical and functional impairment of regulatory T cells
(Tregs), a speciﬁc subset of T cells which is essential for
the control of immunologic tolerance and the prevention of
autoimmunity, in IPF patients [31]. Furthermore, this global
defect was highly correlated with indicators of disease sever-
ity, such as functional parameters, implicating an involve-
ment of Tregs in the ﬁbrotic process.
Despite relative enthusiasm arising from the above ﬁnd-
ings implicating autoimmunity in the pathogenesis of IPF
andhighlightingnoveltherapeutictargetswith clinicalappli-
cations, functional and radiological results from our current
study would downplay the role of T cells during disease pro-
gression. It is therefore conceivable to speculate that the
inability of the drug to be proven eﬃcacious lies both in the
previously suggested minor contribution of T cells in the
pathogenesis of IPF [32] as well as in the inevitable progres-
sive clinical course.
Nevertheless it is important to clarify that there might be
a minority of IPF patients that would beneﬁt from immuno-
suppressive agents such as MMF, including those waiting
for lung transplantation as it happens with patients waiting
for renal transplants where MMF is used to prevent solid-
organ rejection. Based on MMF’s immunosuppressive and
antiproliferative properties and since MMF is often part of
the posttransplant immunosuppressive regimen in these pa-
tients MMF might be considered for use before subjecting
the patient to major surgery [33]. Larger prospective studies
inhighly selective group ofIPF patientsare needed to extract
eﬃcacy outcomes.
Ourstudyhasanumberoflimitations. Firstofall,itisre-
trospective in its nature and underpowered. Secondly, based
on ourdataitisunknown whetherstabilization offunctional
parameters could be attributed to therapeutic intervention
or simply represents a bystander of disease clinical course.
Alternatively, it is impossible to establish a clear relationship
betweendrugeﬀectanddisease outcomemainly duetostudy
design. Larger, prospective randomized studies are needed to
extract outcomes of scientiﬁc rigidity and verify our results,
as occurred with scleroderma associated interstitial lung
involvement. Finally, it is important to underline that in our
case series all the functional parameters showed a gradual
decline, even though statistically insigniﬁcant, evidence that
may be attributed to lack of study power.
Collectively, MMF was well tolerated and safe, showing
no clinically signiﬁcant side eﬀects while it failed to show a
beneﬁcial eﬀect in disease progression as assessed by func-
tional and radiological parameters. Our main ﬁndings un-
derline the current disappointing status in the treatment
ﬁeld of this debilitating disease and highlight the necessity
for future large, prospective, randomised clinical trials of
novel therapeutic agents with versatile properties targeting
multiple pathogenetic pathways.
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